Texas (May 27, 2013) Wax Ink has issued a Loss of Investment Interest rating for Kimberly-Clark Corporation (NYSE: KMB) based on a recent baseline equity review which placed fair value between $44-$54.
The recent close of $103.51 is approximately 291% above the fair value buy target for the stock and approximately 90% above the fair value close target for the stock. The recent close is also 1% above analysts' twelve-month $102.00 median price target for the stock.
The recent close represents a 61% increase in price since the last baseline equity review was conducted in March 2011.
The stock currently has a trailing twelve-month PE Ratio of 17, and a PEG Ratio of 1.9 basis estimated forward earnings growth of 9%.
In the past 52 weeks, share prices have moved between a high of $106.54 and a low of $77.80, placing equilibrium at $95.84.
With the recent close, the stock is trading 3% below the 52 week high, 25% above the 52 week low, and 7% above equilibrium, on an average daily trading volume of 6.42 million shares.
Kimberly-Clark Corporation together with its subsidiaries, manufactures and markets personal care, consumer tissue, and health care products worldwide.
The company's competitors are MedTech Holdings Ltd, The Procter & Gamble Company, L'oreal S.A., Colgate-Palmolive Company, The Clorox Company, Clearwater Paper Corporation, and James Cropper PLC.
All valuations are based on the listed company's most recent SEC annual filing, and all prices are per share.
Wax Ink currently has no investment position in the company mentioned in this alert.
Wax Ink is a baseline equity research company comprised of individual investors, NOT licensed or registered with ANY government agency.
For use by Accredited Investors as defined under Title 17, CFR §230.500, Regulation D
Copyright © 2013 Wax Ink
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.